Supplementary Materials

The PDF file includes:

  • Fig. S1. Titrations of serum IgG by ELISAs specific to MERS-CoV.
  • Fig. S2. Reactivity of anti-SARS-CoV-2 scFv antibodies against recombinant SARS-CoV-2 RBD.
  • Fig. S3. Inhibition of recombinant SARS-CoV-2 S glycoprotein binding to ACE2expressing cells.
  • Fig. S4. In vitro neutralization of SARS-COV-2.
  • Fig. S5. Mapping of 11 nAbs to the overlapping IGH repertoire.
  • Fig. S6. Existence of VL that can be paired with the stereotypic VH.
  • Fig. S7. VJ gene usage among the IG kappa light chain repertoire of patients.
  • Fig. S8. VJ gene usage among the IG lambda light chain repertoire of patients.
  • Fig. S9. Reactivity of phage-displayed scFv clones in phage ELISA.
  • Fig. S11. The nearest-neighbor distance histogram for HCDR3 amino acid sequences in the IGH repertoires of patients.
  • Fig. S12. Frequency scatter plots for NGS data from four libraries after each round of biopanning.
  • Fig. S13. The results of principal component analysis (PCA) applied to the NGS data of four libraries after each round of biopanning.
  • Table S1. Demographic and clinical characteristics.
  • Table S2. SARS-CoV-2 RBD-reactive scFv clones.
  • Table S3. Class-switched IGH clonotypes homologous to E-3B1.
  • Table S4. Human mAbs reactive against MERS-CoV RBD.
  • Table S5. Statistics for the pre-processing of the IGH NGS data.
  • Table S6. Statistics for the pre-processing of the IGκ and IGλ NGS data.
  • Table S7. The RBD-binding prediction clones.
  • Table S8. Primers used in the study.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: